Rachel is a global health industry connector and creative problem solver. She has worked on some of the world's biggest therapies and medical technologies of all time, including the first RNAi therapy (Alnylam’s ONPATTRO), the first therapy for DMD (Sarepta’s EXONDYS 51), the first technology in the world to personalize insulin 24 hrs. a day (Medtronic’s MiniMed 670G), IBM's AI launch into healthcare (Watson Health) and Google's sister life science company (Verily). She has counseled some of the most well-known health/ technology organizations and developed communications strategies for the world's biggest brands (Google, Johnson and Johnson, Medtronic, Pfizer, IBM, Best Buy, Takeda, Sanofi, Shire, Brigham and Women’s, NHS), but she is most proud of her work telling patient stories.

Rachel excels at working with the media to bring health stories to life while making them accessible to stakeholders. With 15-years of communications experience, she is consistently leveraging her long-standing relationships with global agenda-setting reporters across a range of outlets from CNBC, BBC, AP, Reuters, Bloomberg, The Today Show, Newsweek, Financial Times, Fast Company, TIME, Wired, Forbes, WSJ, NYTs, and key health trades like Modern Healthcare, Becker's Hospital Review, Digital Health Journal, GenomeWeb, BioWorld, Drug Discovery Today and many more. Rachel also has investor and analyst relations experience that adds to her ability to highlight market dynamics.

She was named a Power Woman of San Diego 2020 and selected PRSA's PR Professional of the Year in 2011 for her published research on stakeholder engagement. Rachel has built a reputation for her energy, creativity and humor. She received her MA in communications and media studies at SDSU and her BA in English at UMBC.